Divi's Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 17, 2025, approved financial results for Q4&FY2025 and recommended Final Dividend of Rs. 30 per equity share.
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Divi's Laboratories reported strong FY2025 results with consolidated revenue from operations of ₹9,360 crores, up about 19% from ₹7,845 crores in FY2024. Consolidated profit for the year jumped to ₹2,191 crores from ₹1,600 crores, a growth of roughly 37%, while standalone PAT grew even faster at around 40% to ₹2,209 crores. EBITDA margins expanded notably to about 35% from 31% the previous year, helped by operating leverage and a forex gain of ₹48 crores. The Board recommended a final dividend of ₹30 per share (1500% on face value of ₹2), with record date set for July 25, 2025. Additionally, the company's Unit III greenfield project near Kakinada commenced commercial operations, and CFO L. Kishore Babu will superannuate on August 1, 2025, with Venkatesa Perumallu Pasumarthy taking over. The statutory auditors (Price Waterhouse) issued an unmodified (clean) opinion on the financial statements.
Strong revenue and profit growth, expanding margins, and a healthy dividend are positive for shareholders. The leadership transition appears orderly with an internal promotion, and the new plant's commencement adds future capacity for growth.